COX-2--selective NSAIDs.
Hutchison
Rob
R
Presbyterian Hospital, Dallas, Texas, USA.
D011125:Adenomatous Polyposis Coli / Q000188:drug therapy; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy; D001861:Bone Regeneration / Q000187:drug effects; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D004412:Dysmenorrhea / Q000188:drug therapy; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007511:Ischemia / Q000139:chemically induced; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D007668:Kidney / Q000098:blood supply / Q000187:drug effects; D008565:Membrane Proteins; D010146:Pain / Q000188:drug therapy; D018579:Patient Selection; D010974:Platelet Aggregation / Q000187:drug effects; D011451:Prostaglandin-Endoperoxide Synthases; D012307:Risk Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases